PAUL D. MITNICK, M.D.; STANLEY GOLDFARB, M.D.; EDUARDO SLATOPOLSKY, M.D.; JACOB LEMANN, M.D.; RICHARD W. GRAY, M.D.; ZALMAN S. AGUS, M.D.
MITNICK PD, GOLDFARB S, SLATOPOLSKY E, LEMANN J, GRAY RW, AGUS ZS. Calcium and Phosphate Metabolism in Tumoral Calcinosis. Ann Intern Med. 1980;92:482-487. doi: 10.7326/0003-4819-92-4-482
Download citation file:
Published: Ann Intern Med. 1980;92(4):482-487.
We have recently seen a patient with tumoral calcinosis, a syndrome comprising hyperphosphatemia, normocalcemia, normal glomerular filtration rate (GFR), and extensive periarticular calcific masses. Parathyroid hormone (PTH) deficiency or target organ resistance was ruled out by demonstration of normal serum PTH and urinary 3′5′ cyclic AMP excretion and normal response to exogenous PTH and to endogenous stimulation by ethylenediaminetetraacetate. An intrinsic proximal tubular defect allowing enhanced renal PO4 reabsorption was probably present because there was no phosphaturic response to acetazolamine and renal PO4 threshold remained abnormally elevated even after PTH infusion. We then studied the mechanism by which serum calcium level is maintained in the normal range despite hyperphosphatemia and absence of secondary hyperparathyroidism. Normal 1,25-(OH)2 vitamin D was found, suggesting normal gastrointestinal calcium absorption. This, combined with markedly reduced urinary calcium excretion, perhaps a direct effect of hyperphosphatemia, may maintain calcium balance and prevent secondary hyperparathyroidism. A rise in urinary cyclic AMP excretion after furosemide-induced calciuria supports this hypothesis.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Nephrology, Parathyroid Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only